Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) said subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) received China's National Medical Products Administration approval to conduct a clinical trial for FXR0906, a drug candidate for hypertriglyceridemia.
Fosun Pharma (Shenzhen) plans to start a Phase I clinical trial in mainland China after fulfilling relevant conditions, according to Wednesday Hong Kong bourse filing.
Shanghai Fosun Pharma's shares rose nearly 2% in recent trade.